Holen Sie sich die Stockscreener-App
8.25
1.23%
0.10
Handel nachbörslich:
8.25
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $27.13 - MarketBeat
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Will Kura Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan
Kura Oncology (KURA) to Release Earnings on Tuesday - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Weekly Investment Analysts’ Ratings Updates for Kura Oncology (KURA) - Defense World
Kura Oncology's SWOT analysis: stock poised for pivotal year ahead - MSN
Barclays PLC Acquires 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
FY2029 Earnings Forecast for Kura Oncology Issued By Wedbush - MarketBeat
Leerink Partnrs Estimates Kura Oncology Q1 Earnings - MarketBeat
Jennison Associates LLC Purchases New Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
BTIG Research Downgrades Kura Oncology (NASDAQ:KURA) to Neutral - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's What Happened - MarketBeat
Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Kura Oncology (NASDAQ:KURA) Price Target Raised to $40.00 - MarketBeat
Barclays PLC Buys 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Leerink Partnrs Predicts Kura Oncology Q2 Earnings - MarketBeat
Leerink Partnrs Predicts Kura Oncology Q1 Earnings - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Kura Oncology Inc (KURA) - SETE News
Kura Oncology stock target raised to $40 by H.C. Wainwright - MSN
BTIG cuts Kura Oncology stock rating to Neutral - MSN
Kura Oncology (NASDAQ:KURA) Trading 6.7% HigherStill a Buy? - MarketBeat
Leerink Partnrs Comments on Kura Oncology Q2 Earnings - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology reports inducement grants under Nasdaq listing rule - TipRanks
Kura Oncology Expands Team with Strategic Stock Options PackageInside the $8.25/Share Deal - StockTitan
Kura/Kyowa Kirin’s Ziftomenib Scores In NPM1m AML, But Differentiation Is Key - News & Insights
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML - BioWorld Online
SG Americas Securities LLC Buys New Shares in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies - Benzinga India
Kura Oncology falls despite trial success; rival Syndax gains - Seeking Alpha
Kura, Kyowa hail ph. 2 win for leukemia drug, but hold back data - Fierce Biotech
Market Watch Highlights: Kura Oncology Inc (KURA) Ends on an Upturn Note at 9.05 - The Dwinnex
Kura Oncology price target raised to $36 from $34 at Wedbush - TipRanks
BTIG cuts Kura Oncology stock rating to Neutral By Investing.com - Investing.com South Africa
Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed - BioSpace
A new trading data show Kura Oncology Inc (KURA) is showing positive returns. - SETE News
Kura stock slides 7% following ziftomenib update - MSN
Kura to take AML drug ziftomenib to regulators after mid-stage win - The Pharma Letter
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs - The Manila Times
Senior Director, Investor Relations - Built In
Kura stock slides 7% following ziftomenib update (KURA:NASDAQ) - Seeking Alpha
Kura Oncology And Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial - Marketscreener.com
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):